Pharmaceutical
Home » Angiotensin Converting Enzyme (ACE) Inhibitors Market

Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Combination ACE Inhibitors), By Applications (Hypertension, Coronary Artery Diseases, Heart Failure, Myocardial Infarction, Diabetes, Chronic Kidney Disorders) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2023

Price: $4999

Published: | Report ID: 12832 | Category: Pharmaceuticals

Market Insights

This report, titled “Angiotensin-converting enzyme (ACE) Inhibitors Market Studies,” studies various drug types, application types, and geographical scenarios. According to the Cleveland Clinic, an ACE inhibitor is a vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldosterone system (RAAS) plays a key physiologic role in regulating blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II, facilitating the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body.

Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to the World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide, killing nearly 9.4 million people yearly, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the Southeast Asia Region, 36% of adults have hypertension. Thus, the rising prevalence of hypertension and diabetes and the high public awareness related to the early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitor market.

For this study, the global ACE inhibitors market is segmented based on drug type into benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.

For this study, the global ACE inhibitors market is segmented based on application type into hypertension, coronary artery disease, heart failure, myocardial infarction, diabetes, chronic kidney disease, scleroderma, migraine, and others. Market size estimates and forecasts for these segments for 2013–2023 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for 2016–2023, considering 2015 as the base year.

The ACE inhibitors market has been geographically categorized into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and the GCC countries. The market size and forecast for these segments during 2013–2023 and their CAGRs for the period 2016–2023 are provided in this report.

The major key players profiled in the ACE inhibitors market are based on various characteristics such as business description, financial health, budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Johnson & Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

Based on the type of application, the global angiotensin-converting enzyme (ACE) inhibitors market is segmented as follows:

  • Hypertension
  • Coronary artery diseases
  • Heart Failure
  • Myocardial Infarction
  • Diabetes
  • Chronic Kidney Disorders
  • Others (Scleroderma, migraine, and others)

In the base year 2015, hypertension and diabetes applications collectively accounted for the largest market share and are expected to maintain their dominance throughout the forecast period of 2016–2023. The rising prevalence of hypertension and diabetes and the high public awareness related to the early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitor market. According to the World Health Organization (WHO), globally, cardiovascular disease accounts for approximately 17 million deaths a year, or nearly one-third of the total.

Of these, complications of hypertension account for 9.4 million deaths worldwide every year. The global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures. ACE inhibitors also play a vital role in treating chronic kidney diseases and other cardiovascular diseases such as heart failure and myocardial infarction. The chronic kidney disorders application segment was observed as the fastest-moving segment in the overall ACE inhibitors market throughout the 2016–2023.

Based on the type of drug, the global angiotensin-converting enzyme (ACE) inhibitors market is segmented as follows:

  • Benazepril
  • Captopril
  • Enalapril
  • Fosinopril
  • Lisinopril
  • Moexipril
  • Perindopril
  • Quinapril
  • Ramipril
  • Trandolapril
  • Combination ACE inhibitors

Angiotensin-converting enzyme (ACE) inhibitors are high-blood pressure drugs that widen or dilate the blood vessels to improve the amount of blood the heart pumps and lower blood pressure. About half of people (50%) with high blood pressure do not have their condition under control, according to recent data from the Centers for Disease Control and Prevention and the National Health and Nutrition Examination Survey (NHANES). According to the British Hypertension Society, these drugs inhibit the activity of ACE from preventing the formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I.

This process mainly occurs in the blood and tissues, including the kidney, heart, blood vessels, adrenal gland, and brain. Angiotensin II is a potent vasoconstrictor that promotes aldosterone release and facilitates sympathetic activity, along with other potentially harmful effects on the cardiovascular system. The drop in blood pressure secondary to vasodilatation following ACE inhibition is greatest when the renin-angiotensin system is stimulated. Still, ACE inhibitors also lower blood pressure when there is normal or low activity of the renin-angiotensin system. Market experts suggest that lisinopril and ramipril are more popular than comparable drugs due to their convenience in dosage, good insurance coverage, higher efficiency, and low side effects.

For this study, the global angiotensin-converting enzyme (ACE) inhibitor market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In 2015, North America was observed as the largest and most potential regional market for ACE inhibitors. North America comprises the regional markets of the U.S. and Canada, and the rising prevalence of hypertension and kidney disorders is one of the key factors that assist the ACE inhibitor market in this region. The developed healthcare infrastructure, high public awareness related to lifestyle diseases and treatments, and rising research and development activities related to managing lifestyle diseases are the key factors assisting the growth of the North American ACE inhibitor market. Asia Pacific is expected to be the fastest-growing regional market for ACE inhibitors throughout the forecast period.

Over the next six years, the market’s growth in the Asia-Pacific region will likely be centered in China, India, and Japan. Several factors, such as the rising prevalence of hypertension and kidney disorders and high public awareness related to the diagnosis of lifestyle diseases, are assisting the growth of the Asia-Pacific market. The other factors assisting the growth of the ACE inhibitor market are the aging population and other risk factors such as obesity, physical inactivity, and alcohol consumption in this region.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2015 v/s 2023 (Value %)
2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Application Type, 2015 (USD Mn)
2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2015 (Value %)

Chapter 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
3.1 Overview
3.2 Market Drivers
3.3 Market Restraints
3.4 Market Opportunities
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Angiotensin Converting Enzyme (ACE) Inhibitors, by Key Players

Chapter 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Drug Type
4.1 Overview
4.2 Benazepril
4.3 Captopril
4.4 Enalapril
4.5 Fosinopril
4.6 Lisinopril
4.7 Moexipril
4.8 Perindopril
4.9 Quinapril
4.10 Ramipril
4.11 Trandolapril
4.12 Combination ACE Inhibitors

Chapter 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis, By Applications
5.1 Overview
5.2 Hypertension
5.3 Coronary Artery Diseases
5.4 Heart Failure
5.5 Myocardial Infarction
5.6 Diabetes
5.7 Chronic Kidney Disorders
5.8 Others (Scleroderma, Migraine and others)

Chapter 6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Pfizer, Inc.
7.2.1 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 Novartis AG
7.3.1 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 Merck & Co.
7.4.1 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Astra Zeneca plc
7.5.1 Astra Zeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.6 Jhonson and Johnson Limited
7.6.1 Jhonson and Johnson Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.8 Sanofi SA
7.8.1 Sanofi SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.9 Bristol-Myers Squibb Company
7.9.1 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.10 Bayer AG
7.10.1 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.12 Teva Pharmaceutical Industries Ltd.
7.12.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures

FIG. 1 Angiotensin Converting Enzyme (ACE) Inhibitors Market: Research Methodology
FIG. 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2015 v/s 2023 (Value %)
FIG. 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Application Type, 2015 (USD Mn)
FIG. 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2015
FIG. 6 Benazepril Market , 2013 – 2023 (USD Mn)
FIG. 7 Captopril Market, 2013 – 2023 (USD Mn)
FIG. 8 Enalapril Market, 2013 – 2023 (USD Mn)
FIG. 9 Fosinopril Market, 2013 – 2023 (USD Mn)
FIG. 10 Lisinopril Market, 2013 – 2023 (USD Mn)
FIG. 11 Moexipril Market, 2013 – 2023 (USD Mn)
FIG. 12 Perindopril Market, 2013 – 2023 (USD Mn)
FIG. 13 Quinapril Market, 2013 – 2023 (USD Mn)
FIG. 14 Ramipril Market, 2013 – 2023 (USD Mn)
FIG. 15 Trandolapril Market, 2013 – 2023 (USD Mn)
FIG. 16 Combination ACE Inhibitors Market, 2013 – 2023 (USD Mn)
FIG. 17 ACE Inhibitors Application Market in Hypertension, 2013 – 2023 (USD Mn)
FIG. 18 ACE Inhibitors Application Market in Coronary Artery Diseases, 2013 – 2023 (USD Mn)
FIG. 19 ACE Inhibitors Application Market in Heart Failure, 2013 – 2023 (USD Mn)
FIG. 20 ACE Inhibitors Application Market in Myocardial Infarction, 2013 – 2023 (USD Mn)
FIG. 21 ACE Inhibitors Application Market in Diabetes, 2013 – 2023 (USD Mn)
FIG. 22 ACE Inhibitors Application Market in Chronic Kidney Disorders, 2013 – 2023 (USD Mn)
FIG. 23 ACE Inhibitors Application Market in Others, 2013 – 2023 (USD Mn)
FIG. 24 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 25 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 26 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 27 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)
FIG. 28 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market , 2013 – 2023 (USD Mn)

List of Tables

TABLE 1 Market Competition Assessment: Angiotensin Converting Enzyme (ACE) Inhibitors, by Key Players
TABLE 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Drug Type, 2013-2023 (USD Mn)
TABLE 3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Applications, 2013-2023 (USD Mn)
TABLE 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, by Geography, 2013 – 2023 (USD Mn)
TABLE 5 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Astra Zeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Jhonson and Johnson Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Sanofi SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Angiotensin Converting Enzyme (ACE) Inhibitors Market?

The market for Angiotensin Converting Enzyme (ACE) Inhibitors Market is expected to reach USD 11,094.6 Mn By 2023.

What is the Angiotensin Converting Enzyme (ACE) Inhibitors Market CAGR?

The Angiotensin Converting Enzyme (ACE) Inhibitors Market is expected to see significant CAGR growth over the coming years, at (0.5%).

What is the Forecast period considered for Angiotensin Converting Enzyme (ACE) Inhibitors Market?

The report is forecasted from 2016 to 2023.

What is the base year considered for Angiotensin Converting Enzyme (ACE) Inhibitors Market?

The base year of this report is 2015.

Who are the major players in this market?

Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Johnson & Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. are some of the major players in the global market.

HealthCare

Australian Medical Oxygen Concentrators Market

Healthcare

Canada Pharmaceuticals Market

Healthcare

Empty Capsules Market

Vietnam Healthcare Mobility Solutions Market

Saudi Arabia Health and Medical Insurance Market

Healthcare

Europe Telemedicine Market

Healthcare

Europe Parenteral Nutrition Market

Healthcare

Kids Food Supplements Market

Healthcare

Gynecological Examination Chairs Market

Healthcare

Topical Wound Agent Market

HealthCare

Health Insurance Market

Healthcare

Conjugate Vaccines Market

Healthcare

Stance Analyzers Market

Purchase Options

Buy With Trust, Competitive Pricing - In-depth Analysis

$2999

Delivery Format: Excel.

$4999

Designed for the individual purchaser.

$6999

Users located at a single corporate site or regional office.

$9999

Allowed for unlimited sharing globally within one company.


Still Not Sure?

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now